Stereotaxis, Inc. (STXS, Financial) experienced a significant stock movement with a sharp 5.00% decline. The stock currently trades at $2.09 per share with a trading volume of 143,423 shares, demonstrating a turnover rate of 0.17% and a volatility range of 5.82%.
According to recent financial reports, Stereotaxis reported a revenue of $9.20 million and a net loss of $6.19 million, resulting in an earnings per share (EPS) of -$0.08. The company's gross profit stood at $4.10 million, with a price-to-earnings (P/E) ratio of -7.76. Despite these figures, all four institutions rating the stock have issued a 'buy' recommendation, with no hold or sell ratings.
In the medical device sector, where Stereotaxis operates, the industry recorded an overall growth of 0.15%. Notable performers in this sector include Innovative Eyewear Inc, Dentsply, and Sharps Technology Inc., all exhibiting significant gains. Active stocks such as Glucotrack, Inc., Bionano Genomics, Inc., and Nexgel, Inc. showed high turnover rates of 27.82%, 4.52%, and 1.82%, respectively, while Nexgel Inc. C/Wts, Glucotrack, Inc., and Microbot Medical Inc. displayed notable volatility at 37.95%, 24.53%, and 13.80% respectively.
Stereotaxis specializes in robotic technologies aimed at enhancing the treatment of cardiac arrhythmias and performing endovascular procedures. The company's mission focuses on developing and providing robotic systems, instruments, and information solutions for interventional laboratories. These innovations improve precision and safety in patient care, boost laboratory efficiency, and enhance the integration of procedural information. The company’s revenue stems primarily from disposable products, services, and accessories, with the majority of its income originating from the United States.
